摘要
目的观察乙酰半胱氨酸泡腾片辅助治疗痰菌阴性(菌阴)慢性纤维空洞型肺结核的疗效。方法将该院2012年10月至2015年2月收治的100例确诊为慢性纤维空洞型肺结核患者采用随机数字表法分为治疗组和对照组,每组50例。治疗组在原有DL2ZElfx(D:口服对氨基水杨酸异烟肼,每次0.30 g,每天3次;L2:口服利福喷汀,每次0.45 g,每周2次;Z:口服吡嗪酰胺,每次0.50 g,每天3次;E:口服乙胺丁醇,每次0.75 g,每天1次;lfx:口服左氧氟沙星每次0.40 g,每天1次)抗结核治疗基础上加服乙酰半胱氨酸泡腾片,每次600 mg,每天2次,共治疗6个月。对照组采用DL2ZElfx抗结核治疗方案。结果(1)治疗组患者肺部病灶吸收有效率[22%(11/50)]与对照组[16%(8/50)]比较,差异无统计学意义(χ~2=0.58,P=0.444 4)。(2)治疗组患者慢性阻塞性肺病评估测试量表(CAT)总分降幅大于2分,具有临床意义;对照组CAT总分降幅小于2分,无临床意义。(3)治疗组患者治疗后6个月内再住院率[52%(26/50)]明显低于对照组[82%(41/50)],差异有统计学意义(χ~2=10.18,P=0.001 4)。结论乙酰半胱氨酸泡腾片能有效改善菌阴慢性纤维空洞型肺结核患者的临床症状和生活质量,降低并发症发生率,减少住院次数,改善患者预后。口服治疗使用方便且不良反应小,可作为菌阴慢性纤维空洞型肺结核的有效辅助治疗方法。
Objective To observe the curative effect of acetylcysteine effervescent tablet in the treatment of sputumnegative tuberculosis with chronic fibrous cavities. Methods Totally 100 patients with chronic fibrous cavities were selected and randomly divided into treatment group and control group according to the number table method,50 cases in each group. The patients in the treatment group were additional treated with acetylcysteine effervescent tablets at doses of 600 mg twice a day for6 months on the basis of anti-tuberculosis drug combination of DL2ZElfx（D ：isoniazid aminosalicylate tablets,an oral dose of0.3 g,3 times a day;L2：rifapentine,an oral dose of 0.45 g,twice a week;Z：pyrazinamide,an oral dose of 0.50 g,3 times a day;E：ethambutol,an oral dose of 0.75 g,once a day;lfx：levofloxacin,an oral dose of 0.40 g,once a day）.The patients in the control group were treated with DL2 ZElfx. Results（1）The absorption rate of lung lesions in the treatment group and the control group were 22%（11/50） and 16%（8/50）,respectively,the difference had no statistical significance（χ~2=0.58,P=0.444 4）.（2）The total chronic obstructive pulmonary disease assessment test（CAT）score in the treatment group was decreased more than 2 points,which had clinical significance. The average total score of CAT in the control group was reduced less than 2 scores,the difference had no statistical significance（P0.05）.（3） In the treatment group,the hospitalization rate was [52%（26/50）] within the 6 months,which of the control group was [82%（41/50）],the difference was statistically significant（χ~2=10.18,P =0.001 4）. Conclusion The acetylcysteine effervescent tablets can effectively relieve the clinical symptoms,improve the quality of life,reduce complications,reduce the times of hospitalizations and improve the prognosis of the sputum-negative tuberculosis with chronic fibrous cavities patients. Oral therapy is convenient to use and has little adverse reaction,which can be used as an effective me
出处
《现代医药卫生》
2017年第16期2409-2411,共3页
Journal of Modern Medicine & Health
基金
国家卫生和计划生育委员会传染病科技重大专项资助项目(2013ZX10005004)
关键词
乙酰半胱氨酸/治疗应用
片剂
结核
肺/药物疗法
慢性病
治疗结果
Acetylcysteine/therapeutic use
Tablets
Tuberculosis
pulmonary/drug therapy
Chronic disease
Treatment outcome
